Presentation
17 March 2023 Extracellular vesicle-coated prussian blue nanoparticles as targeted phototheranostics for glioblastoma treatment (Conference Presentation)
Taeho Kim, Meghan Hill
Author Affiliations +
Abstract
Glioblastoma is a brain cancer with a five-year survival rate of <5%. MRI and surgical biopsy are typically used to verify the malignancy of a brain tumor, but diagnosis of the aggressive glioblastoma usually occurs at stage IV. Once diagnosed, patients often undergo surgical tumor resection followed by chemotherapy and radiation, which ultimately end in palliative care. There is a current need for a novel theranostic method that allows for early detection and treatment of glioblastoma. Prussian Blue nanoparticles (PBNPs) have been investigated as dual photothermal ablation/photoacoustic imaging agents. Still, due to their inability to cross the blood-brain barrier (BBB), their use in glioblastoma theranostics is limited. To overcome this, we have developed a way to coat PBNPs with a U-87 extracellular vesicle (EV) layer to allow for increased accumulation within glioblastoma tumors due to EV’s innate passage through the BBB.
Conference Presentation
© (2023) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Taeho Kim and Meghan Hill "Extracellular vesicle-coated prussian blue nanoparticles as targeted phototheranostics for glioblastoma treatment (Conference Presentation)", Proc. SPIE PC12395, Colloidal Nanoparticles for Biomedical Applications XVIII, PC1239505 (17 March 2023); https://doi.org/10.1117/12.2650979
Advertisement
Advertisement
KEYWORDS
Nanoparticles

Particles

Tumors

Blood brain barrier

Brain

Laser therapeutics

Magnetic resonance imaging

Back to Top